We gargadi Masu karatunmu makonni biyu baya cewa ra'ayoyin ra'ayoyin suna daukar nauyin editocin mujallolin kimiyya. Mun ce, "Hujjojin da aka gabatar kusan iri ɗaya ne: surutu, ƙwaƙƙwara kuma bisa mafi ƙarancin ingancin shaidar da ake da su." Abin takaici, wannan shine lamarin tare da Binciken Cochrane akan Matsalolin Jiki don katse yaduwar ƙwayoyin cuta na numfashi (A122 a takaice).
Mu ba masu yin abin koyi ba ne, don haka ba za mu iya gani a nan gaba ba, amma mun sami daidai wannan lokacin ta hanyar bayyane da ba zato ba tsammani. Za mu rufe batutuwan da ke kewaye da wannan sabon yanayin farawa daga misalin A122, amma a yanzu, Tom ya aika imel New York Times.
Wannan yanki ya sa Cochrane Hierarchy ya ba da uzuri don rashin haske ba tare da magana ga marubuta ba.
Ji daɗi ko ka firgita kamar yadda Shar310 ya kasance: ya rage na ku.
Akwai karin bayani kan wannan labari yau kan a
-Maryanne Demasi ta ruwaito: Shin Cochrane ya sadaukar da masu bincikensa don gamsar da masu suka?
-Tarihi na Rashin Bayani: Cire abin rufe fuska New York Times ' Zeynep Tufekci
-Kelly K: Duba Aikinku: Inda Maganar Mask ɗin Amurka ta yi kuskure
Za mu ci gaba da yin posting.
An sake bugawa daga marubuta' Mayarwa
-
Tom Jefferson babban mai koyarwa ne a Jami'ar Oxford, tsohon mai bincike a Cibiyar Nordic Cochrane kuma tsohon mai kula da kimiyya don samar da rahotannin HTA game da marasa magunguna na Agenas, Hukumar Kula da Lafiya ta Yanki ta Italiya.
Duba dukkan posts
-
Carl Heneghan darekta ne na Cibiyar Nazarin Shaida ta Magunguna da GP. Masanin ilimin cututtuka na asibiti, yana nazarin marasa lafiya da ke samun kulawa daga likitocin, musamman ma wadanda ke da matsalolin gama gari, tare da manufar inganta tushen shaidar da ake amfani da su a aikin asibiti.
Duba dukkan posts
